Literature DB >> 19474095

Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1.

Emily J Platt1, Miroslawa Bilska, Susan L Kozak, David Kabat, David C Montefiori.   

Abstract

The TZM-bl cell line that is commonly used to assess neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) was recently reported to be contaminated with an ecotropic murine leukemia virus (MLV) (Y. Takeuchi, M. O. McClure, and M. Pizzato, J. Virol. 82:12585-12588, 2008), raising questions about the validity of results obtained with this cell line. Here we confirm this observation and show that HIV-1 neutralization assays performed with a variety of serologic reagents in a similar cell line that does not harbor MLV yield results that are equivalent to those obtained in TZM-bl cells. We conclude that MLV contamination has no measurable effect on HIV-1 neutralization when TZM-bl cells are used as targets for infection.

Entities:  

Mesh:

Year:  2009        PMID: 19474095      PMCID: PMC2715758          DOI: 10.1128/JVI.00709-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Cell-surface receptor for ecotropic murine retroviruses is a basic amino-acid transporter.

Authors:  H Wang; M P Kavanaugh; R A North; D Kabat
Journal:  Nature       Date:  1991-08-22       Impact factor: 49.962

2.  Overcoming interference to retroviral superinfection results in amplified expression and transmission of cloned genes.

Authors:  R K Bestwick; S L Kozak; D Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

3.  Ping-pong amplification of a retroviral vector achieves high-level gene expression: human growth hormone production.

Authors:  S L Kozak; D Kabat
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

4.  Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

Authors:  Ralph Pantophlet; Erica Ollmann Saphire; Pascal Poignard; Paul W H I Parren; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Receptor interference groups of 20 retroviruses plating on human cells.

Authors:  M A Sommerfelt; R A Weiss
Journal:  Virology       Date:  1990-05       Impact factor: 3.616

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion.

Authors:  Gaetano Barbato; Elisabetta Bianchi; Paolo Ingallinella; William H Hurni; Michael D Miller; Gennaro Ciliberto; Riccardo Cortese; Renzo Bazzo; John W Shiver; Antonello Pessi
Journal:  J Mol Biol       Date:  2003-07-25       Impact factor: 5.469

8.  Envelope-binding domain in the cationic amino acid transporter determines the host range of ecotropic murine retroviruses.

Authors:  L M Albritton; J W Kim; L Tseng; J M Cunningham
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1.

Authors:  D Kabat; S L Kozak; K Wehrly; B Chesebro
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  Cell surface receptors for murine leukemia viruses: two assays and their implications.

Authors:  B L Handelin; D Kabat
Journal:  Virology       Date:  1985-01-15       Impact factor: 3.616

View more
  141 in total

1.  Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.

Authors:  Charles Dobard; Sunita Sharma; Amy Martin; Chou-Pong Pau; Angela Holder; Zsuzsanna Kuklenyik; Jonathan Lipscomb; Debra L Hanson; James Smith; Francis J Novembre; J Gerardo García-Lerma; Walid Heneine
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.

Authors:  Stephanie A Freel; Ralph A Picking; Guido Ferrari; Haitao Ding; Christina Ochsenbauer; John C Kappes; Jennifer L Kirchherr; Kelly A Soderberg; Kent J Weinhold; Coleen K Cunningham; Thomas N Denny; John A Crump; Myron S Cohen; Andrew J McMichael; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

3.  Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.

Authors:  Jiong Wang; Gang Zhang; Robert A Bambara; Dongge Li; Hua Liang; Hulin Wu; Hannah M Smith; Nicholas R Lowe; Lisa M Demeter; Carrie Dykes
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter.

Authors:  Haiyan Ji; Zhengtao Jiang; Panpan Lu; Li Ma; Chuan Li; Hanyu Pan; Zheng Fu; Xiying Qu; Pengfei Wang; Junxiao Deng; Xinyi Yang; Jianhua Wang; Huanzhang Zhu
Journal:  Mol Ther       Date:  2016-01-18       Impact factor: 11.454

5.  Structural Insights into HIV-1 Vif-APOBEC3F Interaction.

Authors:  Masaaki Nakashima; Hirotaka Ode; Takashi Kawamura; Shingo Kitamura; Yuriko Naganawa; Hiroaki Awazu; Shinya Tsuzuki; Kazuhiro Matsuoka; Michiko Nemoto; Atsuko Hachiya; Wataru Sugiura; Yoshiyuki Yokomaku; Nobuhisa Watanabe; Yasumasa Iwatani
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

6.  Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity.

Authors:  Zachary S Martinez; Edison Castro; Chang-Soo Seong; Maira R Cerón; Luis Echegoyen; Manuel Llano
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  A CRISPR/Cas9 library to map the HIV-1 provirus genetic fitness.

Authors:  K E Yoder
Journal:  Acta Virol       Date:  2019       Impact factor: 1.162

8.  Screening strategies to identify host factors associated with the early and late stages of HIV-1 life cycle.

Authors:  Yi Hu; Jingxin Zhang
Journal:  Virol Sin       Date:  2013-07-26       Impact factor: 4.327

9.  HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation.

Authors:  Philip R Tedbury; Mariia Novikova; Ayna Alfadhli; Yuta Hikichi; Ioannis Kagiampakis; Vineet N KewalRamani; Eric Barklis; Eric O Freed
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

10.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.